SLD-PQ at 0.25 mg per kg body weight is recommended for MDA targeting Plasmodium falciparum malaria [10]; this dose is considered safe even for G6PD-deficient individuals, and the WHO recommends it may be administered without testing for G6PD deficiency [2, 11–13]. Here, G6PD is linked to G6PD deficiency.